RCKT Quote, Financials, Valuation and Earnings

Artiva Biotherapeutics, Inc. has a net margin of -- compared to Rocket Pharmaceuticals, Inc.'s net margin of -5562.95%. Rocket Pharmaceuticals, Inc.'s return on equity of -64.31% beat Artiva Biotherapeutics, Inc.'s return on equity of -47.44%.

Rocket Pharmaceuticals, Inc. has a consensus price target of $7.95, signalling upside risk potential of 130.57%. On the other hand Artiva Biotherapeutics, Inc. has an analysts' consensus of $17.00 which suggests that it could grow by 281.17%. Given that Artiva Biotherapeutics, Inc. has higher upside potential than Rocket Pharmaceuticals, Inc., analysts believe Artiva Biotherapeutics, Inc. is more attractive than Rocket Pharmaceuticals, Inc..

Rocket Pharmaceuticals, Inc. has a beta of 0.656, which suggesting that the stock is 34.373% less volatile than S&P 500. In comparison Artiva Biotherapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Rocket Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Artiva Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rocket Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Artiva Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Rocket Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Artiva Biotherapeutics, Inc. quarterly revenues of --. Rocket Pharmaceuticals, Inc.'s net income of -$50.3M is lower than Artiva Biotherapeutics, Inc.'s net income of -$21.5M. Notably, Rocket Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Artiva Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rocket Pharmaceuticals, Inc. is -- versus 46.79x for Artiva Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Avalo Therapeutics, Inc. has a net margin of -- compared to Rocket Pharmaceuticals, Inc.'s net margin of -18405.73%. Rocket Pharmaceuticals, Inc.'s return on equity of -64.31% beat Avalo Therapeutics, Inc.'s return on equity of -105.25%.

Rocket Pharmaceuticals, Inc. has a consensus price target of $7.95, signalling upside risk potential of 130.57%. On the other hand Avalo Therapeutics, Inc. has an analysts' consensus of $34.38 which suggests that it could grow by 79.32%. Given that Rocket Pharmaceuticals, Inc. has higher upside potential than Avalo Therapeutics, Inc., analysts believe Rocket Pharmaceuticals, Inc. is more attractive than Avalo Therapeutics, Inc..

Rocket Pharmaceuticals, Inc. has a beta of 0.656, which suggesting that the stock is 34.373% less volatile than S&P 500. In comparison Avalo Therapeutics, Inc. has a beta of 0.839, suggesting its less volatile than the S&P 500 by 16.057%.

Rocket Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avalo Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rocket Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Avalo Therapeutics, Inc. pays out -- of its earnings as a dividend.

Rocket Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Avalo Therapeutics, Inc. quarterly revenues of --. Rocket Pharmaceuticals, Inc.'s net income of -$50.3M is lower than Avalo Therapeutics, Inc.'s net income of -$30.6M. Notably, Rocket Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Avalo Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rocket Pharmaceuticals, Inc. is -- versus 1,110.83x for Avalo Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -- compared to Rocket Pharmaceuticals, Inc.'s net margin of 33.68%. Rocket Pharmaceuticals, Inc.'s return on equity of -64.31% beat Merck & Co., Inc.'s return on equity of 39.63%.

Rocket Pharmaceuticals, Inc. has a consensus price target of $7.95, signalling upside risk potential of 130.57%. On the other hand Merck & Co., Inc. has an analysts' consensus of $110.04 which suggests that it could grow by 4.76%. Given that Rocket Pharmaceuticals, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Rocket Pharmaceuticals, Inc. is more attractive than Merck & Co., Inc..

Rocket Pharmaceuticals, Inc. has a beta of 0.656, which suggesting that the stock is 34.373% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

Rocket Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.12% to investors and pays a quarterly dividend of $0.85 per share. Rocket Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Rocket Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Rocket Pharmaceuticals, Inc.'s net income of -$50.3M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Rocket Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 13.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rocket Pharmaceuticals, Inc. is -- versus 4.14x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Rocket Pharmaceuticals, Inc.'s net margin of -255.85%. Rocket Pharmaceuticals, Inc.'s return on equity of -64.31% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Rocket Pharmaceuticals, Inc. has a consensus price target of $7.95, signalling upside risk potential of 130.57%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -81.4%. Given that Rocket Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Rocket Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Rocket Pharmaceuticals, Inc. has a beta of 0.656, which suggesting that the stock is 34.373% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Rocket Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Rocket Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Rocket Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Rocket Pharmaceuticals, Inc.'s net income of -$50.3M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Rocket Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rocket Pharmaceuticals, Inc. is -- versus 8.88x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.